The HGF/c-Met Mechanism
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is an angiotensin IV analog developed at Washington State University. It works by potentiating Hepatocyte Growth Factor (HGF), which then binds its receptor c-Met on neurons.
This HGF/c-Met signaling cascade is one of the most powerful drivers of synaptic plasticity in the CNS — and Dihexa is a superagonist of this pathway, reportedly 7-10 million times more potent than BDNF in dendritic spine formation assays.
Dendritic Spine Architecture and Memory
Memory formation is physically encoded in dendritic spines — microscopic protrusions on neuron trees that form synapses. Long-term potentiation (LTP) strengthens existing spines, but Dihexa drives the creation of entirely new spines (de novo spinogenesis), effectively wiring new cognitive circuitry.
This makes Dihexa profoundly different from cholinergic nootropics (racetams, acetylcholine precursors) which merely enhance existing transmission. Dihexa builds new hardware.
Administration Forms and Timing
Dihexa's high lipid solubility enables multiple routes: oral (limited bioavailability), sublingual (moderate), and transdermal via DMSO formulations (high CNS penetration). The transdermal route is most popular due to practical dosing convenience.
Due to its uniquely long CNS half-life and the sustained neuroplastic effects it induces, Dihexa is typically cycled 1-2 times per week rather than daily, avoiding over-saturation of the HGF/c-Met pathway.
